Oragenics, Inc. announced on July 2, 2025, the successful closing of its previously announced public offering of Series H Convertible Preferred Stock and Warrants. The company secured total gross proceeds of approximately $16.5 million.
As part of the transaction, Oragenics issued 660,000 shares of Series H Convertible Preferred Stock and Warrants to purchase up to 660,000 additional shares of Series H Convertible Preferred Stock. Each unit was sold at a combined public offering price of $25.00.
The company intends to use the net proceeds to advance the clinical development of ONP-002, support other research and development activities, repay a $3 million bridge note, and fund working capital. CEO Janet Huffman expressed encouragement by the strong investor support, which reflects confidence in the company's science and strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.